Drugs are contained in a multilayered lipid crystal matrix by the nanocochleate drug delivery vehicle, which makes distribution safe and efficient. Cochleates are significant particles consisting of spirally twisted, enormous, continuous lipid bilayer sheets without an interior aqueous phase between them. Nanocochleates have greater stability compared to liposomes, making them a promising delivery method. It also has higher encapsulation efficiency due to its rod form. The bilayered structure allows for more regulated medication storage. Aside from several benefits, they have drawbacks since they require specialized storage conditions.¹

Stable phospholipid-cation precipitates made mostly of calcium and phosphatidylserine are the building blocks of nanocochleate delivery vehicles. The overall development of the nanocochleate is made up of solid layers and components that are sealed within its core and stay intact, despite the possibility of the exterior layers being exposed to harsh environments or enzymes. Nanocholeates can be utilized to encapsulate both hydrophobic and hydrophilic drugs because of their surfaces’ dual hydrophobic and hydrophilic properties.² Encochleation nanotechnology has the potential to improve various aspects of formulated products, such as ease of production, formulation quality, sustained drug release, processing and shelf-life stability and biodegradability for systemic administration. Encapsulating physiologically significant molecules, nanocochleate shields them from environmental and gastrointestinal enzyme-induced breakdown.³ Cochleates hold onto their bilayer structures of phospholipids. Because of their extreme flexibility, these solid particles may easily remove the bridging counter ions from the interbilayer gaps and transform into liposomes. Because of their special qualities, cochleates are the ideal vehicle for delivering insoluble materials that can be incorporated into phospholipid bilayers without causing liposome instability.⁴

Negatively charged phospholipid bilayers called cochleate and nanocochleate interact with multivalent counter ions like Zn²⁺ or Ca²⁺ to generate bridging agents that allow the bilayers to form spiral rolls that resemble cigars. Because of their solid matrix, cochleates, as a particulate structure, have special qualities above liposomes, such as greater mechanical stability and better protection for pharmaceuticals possessed.⁵ The vast multilayer sheets with hydrophobic surfaces prefer to roll up into a cigar-like form in order to reduce the water interactions. Dehydration of the phosphatidyl head group is the molecular mechanism and it is essential for bilayers to approach closely and for the development of cochleate cylinders to start (Figure 1). The lipid bilayer is oriented at a repeating distance close to 54 Å.⁶

The drug is believed to be released by the nanocochleates when their lipid bilayer unites with the cell membrane and the required pharmacological activity may be attained.⁴ An further conjecture highlights the chances of phagocytosis using phosphatidylserine receptors. These are typical for the exterior cochleate film and the lipid layer of macrophages. The collected medication enters the cytoplasm of macrophages when cochleate approaches their lipid film and connects with them.⁷

The following techniques are often used to prepare nanocochleates.⁸

Hydrogel technique, Trapping technique, Liposome before cochleates dialysis technique. Direct calcium dialysis technique and Binary aqueous- aqueous emulsion technique.

Small unilamellar drug-loaded liposomes are generated using the hydrogel approach and introduced to polymer-A. Next, polymer-B receives the addition of two dispersions. The two polymers are immiscible with one another and as a result, an aqueous two-phase system is formed. A cation salt solution diffuses into the second polymer and then into the particles that contain the polymer in a two-phase system. As a result, cationic cross-linkage and small-sized cochleate are formed in the polymer (Figure 2). The polymer in the created cochleates is removed by washing; the polymer may then be resuspended in physiological buffer.⁵

Trapping method involves several key steps, a phospholipid solution is prepared and the drug of interest is dissolved in a compatible solvent. The lipid solution is then mixed with an aqueous buffer and subjected to mechanical agitation, promoting the formation of lipid bilayers that transition into cochleate structures. During this process, the drug becomes encapsulated within the cochleates. After formation, the nanocochleates are purified through centrifugation or dialysis to remove unbound components (Figure 3). Finally, characterization techniques like dynamic light scattering and transmission electron microscopy are used to assess size, morphology and drug loading efficiency, ensuring the nanocochleates are suitable for drug delivery applications.⁹

Lipid and detergent are added to the liposomes during their initial production using this process. It’s a two-step process wherein liposomes are created by first removing the detergent using dialysis. After that, the generated liposomes are used for dialysis against a Calcium Chloride (CaCl₂) solution, which causes nanocochleates to develop. Because the generated intermediate liposomes are tiny, the created nanocochleates are small as well. This method is typically applied to hydrophobic materials, including membrane proteins. Using this technique, 50-100 nm-sized nanocochleates may be produced (Figure 4).¹⁰

The cochleates will be the same size and this approach does not include the formation of transitional liposomes, unlike the liposome used in the prior cochleate dialysis method. Calcium chloride configuration is immediately dialyzed against the lipid and more efficient combination. The tension between the formation of calcium and the cleanser’s release from the cleanser/lipid/drug micelles produces a thin, highly layered structure in this manner. Phosphatidylserine, cholesterol and a preset concentration of polynucleotide are mixed in a non-ionic cleanser and extraction cushion and the mixture is vortexed for 5 min. After that, the produced clear solution is dialysed at room temperature against three different buffer modifications. While 3 mM Ca²⁺ is enough, the last dialysis is carried out in a solution containing 6 mM Ca²⁺. DC cochleate is the resulting white calcium phospholipid (Figure 5).¹¹

Using a film technique or a high pH, tiny liposomes are encapsulated in this manner and then mixed with a polymer, such dextran. A second, non-miscible polymer (like Stake) is then injected with the dextran/liposome stage. After that, the calcium was applied and spread progressively, first to one stage and then to the subsequent framing nanocochleates. The cochleates framed with this method have molecules smaller than 1000 nm.¹²

Figure 1:
Schematic representation of Nanocochleates.

Figure 2:
Hydrogel method for the preparation of Nanocochleates.

As phospholipids used to generate nanocochleates which results from a natural source, they are less resistant to oxidation. When the cationic salt reacts with the phospholipid, a tight connection is formed, resulting in the creation of stable nanocholeates. The medication is included within the solid phospholipid bilayer series. Following their synthesis, nanocochleates are lyophilized, which increases their stability over time and allows them to be reconstituted before usage by adding the appropriate vehicle. This implies that this new technology is superior to existing nanocarrier systems.¹³

The liposomal and cochleate dispersions’ mean particle sizes were calculated using the Malvern 2000SM (Malvern, UK) laser diffraction technique. For the analysis, a 30±2°C temperature and a 90° angle of detection were employed. The volume mean diameter, the average diameter of a sphere whose volume is equal to the particle under measurement-was utilized to express the mean vesicle size.¹⁴

Figure 3:
Trapping method for the preparation of Nanocochleates

A sorptometer is commonly used to measure the specific surface area of a freeze-dried Nanocochleate product. The following formula may be used to calculate the specific surface area,

Where,

d is the cochleate’s diameter, ρ is its density and A is its specific surface area.

While the determined and computed specific surface areas generally agree, sometimes residual surfactant might lead to discrepancies in the observed results.⁶

Using a gas pycnometer and either air or helium, one may find the density of nanocochleates. The result obtained with air and helium is particularly clear because of the structure’s porosity and specific surface area.¹⁵

The unbound medication is separated from the supernatant by centrifuging the redispersed nanocochleates suspension for 40 min at 25° and 15,000 rpm. After an appropriate dilution, the drug dosage in the supernatant may then be measured using UV-vis spectrophotometry.¹⁶

Separate the cochleates (100 μL) into tubes that have been centrifuged.¹⁷ One milliliter (mL) of ethanol and sixty microliters of pH 9.5 EDTA were mixed during the vortexing process. An appropriate analytical method is used to quantify the absorbance of the solution and the following formula is used to compute the entrapment efficiency.

Figure 4:
Liposome before cochleates dialysis method.

Figure 5:
Direct calcium dialysis method.

The in vitro release profile of nanocochleates can be ascertained using diffusion cells, conventional ones dialysis, or the recently developed modified ultra-filtration methods that employ double chamber diffusion cells on an agitated platform with phosphate buffer. A hydrophilic Millipore membrane with poor protein binding capacity divides the two chambers. Using well-established methods, the receptor compartment is routinely examined for the release of medication after nanocochleates are added to the donor chamber. The in vitro release behavior of the nanocochleates is also ascertained using the modified ultra-filtration approach. Here, the buffer-containing ultra-filtration cell is shaken prior to the direct addition of Nanocochleate. Using an ultra-filtration membrane, aliquots of the dissolving media are filtered at various times with a nitrogen pressure of <2. The medicine is then examined using standard procedures once it has been released.¹⁸

A study using Fourier Transform Infrared spectroscopy (FTIR) identifies the compound’s purity and functional groups that are present.¹⁹ To prepare samples, combine them with KBr. Samples are then put into the holder. The specific wave number ranges are covered by scanning the spectra at room temperature.

Lipid state is established using an examination with differential scanning calorimetry.²⁰ The samples are heated steadily at 10°C/ min within perforated, hermetically sealed aluminum pans. The temperature range of the samples is -10 to 180°C. Nitrogen gas is fed into the system at a rate of 100 mL/min to keep the atmosphere inert.

A refractive index detector can be used in Gel Permeation Chromatography (GPC) to determine the molecular weight of the polymer and its dispersion in the matrix. Unlike what was demonstrated using GPC, which is the result of one or a few lengthy polymer chains rolling up, multiple small oligomeric subunits entangle to form PACA nanocochleates.²¹

The surface morphology of nanocochleates is investigated using Transmission Electron Microscopy (TEM).¹¹ For this investigation, the diluted sample is ready by dropping it onto a carbon-coated copper grid, which forms a thin liquid layer. After eliminating any excess solution from the sample, it is examined and captured on camera using a TEM operating at an 80 kV accelerating voltage.

It is important to consider the form and magnitude of surface charge on a nanocrystal because it influences the molecule’s electrostatic interactions with bioactive chemicals and its interactions with the biological environment. The velocity of colloidal particles in an electric field can be used to measure their surface charge, especially sodium chorochleate. Naphthocyanine velocities may be quickly and accurately calculated using laser light scattering methods like velocimetry or Laser Doppler Analysis (LDA/LDV). Another way to quantify colloidal particle surface charge is by electrophoretic mobility. The biodistribution of medication-carrying nanocochleate is significantly influenced by the charge composition. Human serum and phosphate saline buffer are frequently used to test the electrophoretic mobility of NP. The phosphate saline buffer’s pH of 7.4 drops as a result of an ionic interaction between the buffer’s constituent parts and the charged surface of nanocochleate. The Helmholtz-Smoluchowski equation and an electrophoretic mobility measurement can be used to determine the zeta potential.²²

The hydrophobicity of nanocochleates’ surface affects how colloidal particles interact with their biological surroundings. The bio-fate of nanocochleates and their component components is influenced by the mix of hydrophobicity and hydrophilicity. The characteristics of blood elements that nanocochleates interact with hydrophobically are regulated by their hydrophobicity. Surface hydrophobicity has been assessed using a variety of techniques, such as hydrophobic interaction chromatography, two-phase partitioning, adsorption of hydrophobic fluorescence or radiolabelled probes and contact angle measuring.²³

To investigate the relationship between cochleates and cell membranes, 2% fluorescent lipid is combined with negatively charged lipids to form fluorescent cochleates. The surfaces of the cells light and become visible under fluorescent microscopes when cochleates come into contact with the cell membrane due to a luminous lipid transfer.⁶

As phospholipids used to generate nanocochleates come from a natural source, they are less resistant to oxidation potential. When the phospholipid and cationic salt react, a tight connection is formed, resulting in the creation of stable nanocholeates. The medication is included within the solid phospholipid bilayer series. Following their synthesis, nanocochleates are lyophilized, which increases their stability over time and allows them to be reconstituted by adding the appropriate vehicle before to use. This implies that this new technique is superior to existing nanocarrier technologies. For stability tests, cochleates dispersions can be stored for three months at 2 to 8°C and 25±2°C/60% RH. Changes in cochleate particle size and Entrapment Efficiency (% EE) are used to assess the formulation’s stability.²⁴

The stable lipid-based delivery forms known as nanocochleates differ greatly from liposomes in terms of their shapes and characteristics. One possible method of raising the nanocochleate’s stability throughout time in terms of both chemical and physical aspects. It is anticipated that solid lyophilizates will be more chemically and physically stable than liquid lipidic dispersions.⁶ To keep the nanoparticulate solution stable, common cryoprotective substances such sorbitol, mannose, trehalose and glucose are mixed. It is possible to lyophilize nanocochleates into a powder and store them at 40°C. Before being administered in vivo or in vitro, lyophilized cochleate can be reconstituted with liquid. The shape or functions of cochleate are not negatively impacted by lyophilisation.¹

One of the primary uses of nanocochleates is in drug delivery.²⁹ Numerous medications, including tiny molecules, peptides, proteins and nucleic acids, can be enclosed in these nanostructures. Nanocochleates protect the encapsulated drug from degradation, enhance its stability and provide controlled release, leading to improved therapeutic outcomes (Table 1).

Nanocochleates have shown potential in cancer therapy by encapsulating chemotherapeutic agents and targeting them to tumor cells.³⁰ This targeted delivery approach can enhance the efficacy of chemotherapy while minimizing systemic toxicity and side effects (Table 1).

Nanocochleates can encapsulate antibiotics, antifungal agents and antiviral drugs to treat several infections.³¹ The unique structure of cochleates enables efficient delivery of antimicrobial agents to infected cells or tissues, improving therapeutic outcomes (Table 1).

Nanocochleates have been explored as vaccine delivery vehicles for antigens and adjuvants.³² They can enhance the stability of vaccines, promote antigen intake by antigen-presenting cells and induce robust immune responses, making them promising candidates for vaccine development (Table 1).

For gene therapy applications, nucleic acid-based therapies like as mRNA, siRNA and plasmid DNA can be delivered using nanocochleates.³³ They protect nucleic acids from degradation, enable cellular intake and enhance targeted delivery to specific tissues or cells (Table 1).

Nanocochleates have potential applications in diagnostics, particularly in imaging and biosensing.³⁴ Nanoparticles are useful tools for disease monitoring and diagnostic imaging because they may be functionalized with imaging agents or targeting ligands to enable viewing of certain tissues or biomolecules.

Nanocochleates can encapsulate bioactive compounds such as vitamins, antioxidants and phytochemicals for use in nutraceuticals and cosmeceuticals.³⁵ They improve the stability and bioavailability of these compounds, allowing for enhanced efficacy in dietary supplements and skincare products.

Growth factors, cytokines and other bioactive compounds can be delivered using nanocochleates to aid in tissue regeneration and wound healing in regenerative medicine.³⁶ They can be tailored to specific tissue types and used in therapies for tissue engineering and regenerative therapies.

Nanocochleates are innovative lipid-based vesicles that enhance drug delivery and therapeutics. They offer advantages like improved stability, biocompatibility and targeted delivery, capable of encapsulating a wide range of medications from small compounds to nucleic acids and proteins. By protecting drugs from degradation and facilitating transport to specific tissues, nanocochleates address challenges of conventional drug delivery, such as poor solubility and bioavailability. Their customizable properties like size, surface charge and release kinetic allow for tailored systems that improve efficacy and patient compliance. Continued research is crucial to fully realize their potential in transforming treatments and enhancing patient outcomes.